Valeant hopes to initiate earnings of RELISTOR Tablets from the U.S. at the thirdquarter of 20-16. “Opioid-induced constipation signifies a long-term and Potentially debilitating complication of opioid therapy for tens of thousands of patients experiencing chronic pain,” remarked Joseph C. Papa,” Chief Executive Officer of Valeant. “We believe Cosmetic RELISTOR represents a fresh alternative cure for OIC, and now we anticipate presenting the convenient oral formula when practicable.”
“We're thrilled This landmark for RELISTOR was attained, And that patients afflicted by OIC may get this brand new treatment option,” stated Mark Baker, Chief Executive Officer of Progenics. “We expect industry to be amenable to a convenient oral pill formula of RELISTOR's well-established subcutaneous groundwork. We'd like to thank you, specifically, Dr. Tage Ramakrishna and also Dr. Robert Israel of Valeant to their job over Several Years from the clinical development of RELISTOR.”
“RELISTOR Includes a Special mechanism of action which contrasts into mu-opioid “This represents a genuine breakthrough in the procedure of OIC, also addresses a large and growing demand in the area of pain control ” Now, the FDA accepted RELISTOR Tablets for its Treatment of OIC in adults who have chronic non-cancer painkillers. Previously, RELISTOR Subcutaneous Injection has been accepted at 2008 For the therapy of OIC in adults who have complex disease that are Receiving palliative care also in 2014 for its treating OIC in adults
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.